CA Patent

CA3198798A1 — Improved synthesis of crac channel inhibitors

Assigned to Calcimedica Inc · Expires 2022-05-19 · 4y expired

What this patent protects

Provided herein is an improved synthetic method for the production of CRAC channel inhibitors. The synthetic method provides a method for producing highly pure CRAC channel inhibitors for clinical testing.

USPTO Abstract

Provided herein is an improved synthetic method for the production of CRAC channel inhibitors. The synthetic method provides a method for producing highly pure CRAC channel inhibitors for clinical testing.

Drugs covered by this patent

Patent Metadata

Patent number
CA3198798A1
Jurisdiction
CA
Classification
—
Expires
2022-05-19
Drug substance claim
No
Drug product claim
No
Assignee
Calcimedica Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.